Agoracom Blog

@Novamind_Inc $NM.ca Announces Symbol Change on OTC Market To $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 9:13 AM on Friday, February 19th, 2021
  • To commence trading on the OTC Pink Market under the symbol “NVMDF” effective February 19, 2021.
  • The Company’s common shares will continue to trade on the Canadian Securities Exchange under the symbol “NM”.

TORONTO, ON / ACCESSWIRE / February 19, 2021 / Novamind Inc., (CSE:NM)(OTC PINK:NVMDF) (“Novamind” or the “Company”) a mental health company specialized in psychedelic medicine, announces that its common shares, previously listed for trading on the OTC Pink Market in the United States under the symbol “HNLMF”, are to commence trading on the OTC Pink Market under the symbol “NVMDF” effective February 19, 2021. The Company’s common shares will continue to trade on the Canadian Securities Exchange under the symbol “NM”.

Novamind intends to apply to list its common shares on the OTCQB Market in the near future. The OTCQB Market is an established financial market in the United States for promising, investor-focused companies based in America or internationally.

About Novamind

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly-owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit www.novamind.ca.

Read more: https://agoracom.com/ir/Novamind/forums/discussion/topics/755663-novamind-announces-symbol-change-on-otc-market-to-nvmdf/messages/2304371#message

Tags: , , , ,

Comments are closed.